# Cantargia > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/cantargia). ## Overview Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases. The company's innovative approach centers around the IL1RAP molecule, which is found on cancer cells and is involved in disease-causing inflammation. Cantargia's drug candidates, such as Nadunolimab and CAN10, aim to provide new treatment options for serious and debilitating diseases. The company operates primarily through strategic partnerships and has a strong intellectual property portfolio with over 100 patents globally. ## Products & services • Nadunolimab for pancreatic and non-small cell lung cancer • CAN10 for autoimmune and inflammatory diseases • Strategic partnerships for drug development • Antibody-based therapies targeting IL1RAP • Research and development of next-generation antibody formats - **Cancer Therapies** (50%) — Includes drugs targeting cancer cells, such as Nadunolimab. - **Autoimmune and Inflammatory Therapies** (30%) — Includes treatments like CAN10 for autoimmune diseases. - **Strategic Partnerships** (20%) — Collaborations for drug development and commercialization. - Nadunolimab for pancreatic and non-small cell lung cancer - CAN10 for autoimmune and inflammatory diseases - Strategic partnerships for drug development - Antibody-based therapies targeting IL1RAP - Research and development of next-generation antibody formats ## Customers Cantargia's customers primarily include pharmaceutical companies and healthcare providers seeking advanced treatments for cancer and autoimmune diseases. The company's strategic partnerships, such as the one with Otsuka Pharmaceuticals, highlight its focus on collaboration for drug development and commercialization. Healthcare providers benefit from Cantargia's innovative therapies, which address unmet medical needs in oncology and immunology. The company's focus on targeted antibody-based treatments attracts interest from entities looking to enhance their therapeutic offerings in these areas. - **Pharmaceutical Companies** (primary) — They partner with Cantargia for innovative drug development. - **Healthcare Providers** (secondary) — They use Cantargia's therapies to treat cancer and autoimmune diseases. - **Strategic Partners** (emerging) — They collaborate on drug development and commercialization. - Pharmaceutical companies seeking innovative cancer treatments - Healthcare providers looking for advanced immunological therapies - Strategic partners interested in collaborative drug development - Entities focused on addressing unmet medical needs in oncology and immunology ## Geography Cantargia is headquartered in Lund, Sweden, and operates primarily through partnerships with global pharmaceutical companies. The company has a significant presence in Japan, where it has generated substantial revenue through its partnership with Otsuka Pharmaceuticals. Cantargia's strategic focus on international collaborations allows it to leverage global expertise and market access. The company's geographic strategy is centered around expanding its reach in key markets for oncology and immunology therapies. - Headquartered in Lund, Sweden - Significant revenue from partnership with Otsuka in Japan - Focus on international collaborations for market access - Expanding reach in key oncology and immunology markets ## Strategy Cantargia's strategic priorities include advancing its pipeline of antibody-based therapies, particularly Nadunolimab and CAN10, through clinical trials and towards market registration. The company aims to strengthen its position in the oncology and immunology sectors by leveraging strategic partnerships and expanding its global presence. Cantargia is focused on maintaining a robust intellectual property portfolio to protect its innovations and create competitive barriers. The company is also committed to operational excellence and disciplined execution to maximize shareholder value and achieve long-term growth. - **Advance Nadunolimab and CAN10** (medium-term) — To achieve market registration and address unmet medical needs. - **Leverage strategic partnerships** (short-term) — To expand global market access and enhance drug development. - **Maintain strong IP portfolio** (long-term) — To protect innovations and create competitive barriers. - Advance Nadunolimab and CAN10 through clinical trials - Leverage strategic partnerships for global market access - Maintain a strong intellectual property portfolio - Focus on operational excellence and disciplined execution ## Risks Cantargia faces significant risks inherent in the biotech industry, including the high cost and uncertainty of drug development. The company is exposed to technological risks, such as insufficient efficacy or intolerable side effects of its drug candidates. Regulatory challenges and the need for successful clinical trials add to the complexity. Additionally, Cantargia's reliance on strategic partnerships introduces risks related to collaboration dynamics and milestone achievements. Market competition and changes in healthcare regulations also pose potential threats to the company's growth and profitability. - **Technological risks in drug development** [critical] — Potential for insufficient efficacy or intolerable side effects. - **Regulatory challenges** [high] — Need for successful clinical trials and approvals. - **Reliance on strategic partnerships** [high] — Dependency on partners for milestone achievements and commercialization. - High cost and uncertainty of drug development - Technological risks like insufficient efficacy or side effects - Regulatory challenges and clinical trial success requirements - Reliance on strategic partnerships for development and commercialization - Market competition and changes in healthcare regulations ## Accounting Cantargia's financial reporting is influenced by the timing of revenue recognition from strategic partnerships, such as milestone payments and royalties. The company's revenue can fluctuate significantly due to the nature of these agreements. Foreign exchange rate changes also impact financial results, as seen in the reporting of operating expenses. Cantargia applies alternative performance measures to provide a clearer view of its financial position. The company's accounting policies are consistent with Swedish and international standards, ensuring transparency and comparability. - **Revenue recognition from milestone payments** — high - **Foreign exchange rate changes** — medium - Revenue recognition from milestone payments and royalties - Fluctuations in revenue due to strategic partnership agreements - Impact of foreign exchange rate changes on financial results - Use of alternative performance measures for financial clarity --- *Last updated: 2026-08-11T04:04:51.447645+00:00*